Previous studies demonstrate that syndecan‐2 inhibition (via SDC2 knockdown or syndecan‐2‐peptide) within the epithelial compartment of tumours also reduces tumour growth and metasatasis in immune‐compromised models.31, 46. Here, SDC2 is linked to neoplasm.